NEW YORK (TheStreet) -- Shares of Verisk Analytics(VRSK) - Get Report are lower by 0.41% to $77.95 on Friday morning, as asset management firm Carlyle Group (CG) is in advanced discussions to purchase the company's healthcare information technology division, sources told Reuters.

The Washington, D.C.-based firm is in the lead so far for the company's Verisk Health unit, which has also received interest from other firms such as Veritas Capital Fund Management, the sources added.

Verisk initially hoped to receive $1 billion for the unit, but the sources said Carlyle's offer was significantly below that price.

Jersey City, NJ-based Verisk is a provider of information about risk to insurance, healthcare, financial services, government, supply chain and risk management markets.

Previously, Carlyle has invested in Ortho-Clinical Diagnostics, a former segment of Johnson & Johnson (JNJ), and contract research organization Pharmaceutical Product Development, Reuters noted.

Shares of Carlyle Group are gaining by 2.05% to $16.40 on Friday morning.

Separately, TheStreet Ratings Team has a "Buy" rating with a score of A- on Verisk stock.

The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, growth in earnings per share, compelling growth in net income and expanding profit margins.

Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

You can view the full analysis from the report here: VRSK

Image placeholder title